Crystal structure of the complex between programmed death-1 (PD-1) and its ligand PD-L2

Proceedings of the National Academy of Sciences of the United States of America

Volumn 105, Issue 30, 2008, Pages 10483-10488

  Lázár Molnár, Eszter ^a   Yan, Qingrong ^a   Cao, Erhu ^a   Ramagopal, Udupi ^a   Nathenson, Stanley G ^a   Almo, Steven C ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

Coinhibition; Costimulation; Inhibitory receptor; T cell activation

Indexed keywords

PROGRAMMED DEATH 1; PROGRAMMED DEATH LIGAND 2; TUMOR PROTEIN;

ARTICLE; BINDING AFFINITY; COMPLEX FORMATION; CONTROLLED STUDY; CRYSTAL STRUCTURE; HUMAN; HUMAN CELL; MUTAGENESIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; T LYMPHOCYTE ACTIVATION;

AMINO ACID SEQUENCE; ANIMALS; ANTIGENS, SURFACE; APOPTOSIS REGULATORY PROTEINS; CRYSTALLOGRAPHY, X-RAY; ESCHERICHIA COLI; LIGANDS; LYMPHOCYTE ACTIVATION; MICE; MOLECULAR SEQUENCE DATA; MUTATION; PEPTIDES; PROTEIN CONFORMATION; PROTEIN STRUCTURE, SECONDARY; SEQUENCE HOMOLOGY, AMINO ACID; T-LYMPHOCYTES;

MURINAE;

EID: 48749095324     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.0804453105     Document Type: Article

References (28)

1. Greenwald RJ, Freeman GJ, Sharpe AH (2005) The B7 family revisited. Annu Rev Immunol 23:515-548.
2. Bhatia S, Edidin M, Almo SC, Nathenson SG (2005) Different cell surface oligomeric states of B7-1 and B7-2: Implications for signaling. Proc Natl Acad Sci USA 102:15569-15574.
3. Okazaki T, Honjo T (2007) PD-1 and PD-1 ligands: From discovery to clinical application. Int Immunol 19:813-824.
4. Freeman GJ, et al. (2000) Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med 192:1027-1034.
5. Latchman Y, et al. (2001) PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat Immunol 2:261-268.
6. Okazaki T, Maeda A, Nishimura H, Kurosaki T, Honjo T (2001) PD-1 immunoreceptor inhibits B cell receptor-mediated signaling by recruiting src homology 2-domain-containing tyrosine phosphatase 2 to phosphotyrosine. Proc Natl Acad Sci USA 98:13866-13871.
7. Okazaki T, Honjo T (2006) The PD-1-PD-L pathway in immunological tolerance. Trends Immunol 27:195-201.
8. Nishimura H, Nose M, Hiai H, Minato N, Honjo T (1999) Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity 11:141-151.
9. Nishimura H, et al. (2001) Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice. Science 291:319-322.
10. Zang X, Allison JP (2007) The B7 family and cancer therapy: Costimulation and coinhibition. Clin Cancer Res 13:5271-5279.
11. Sharpe AH, Wherry EJ, Ahmed R, Freeman GJ (2007) The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection. Nat Immunol 8:239-245.
12. Zhang X, et al. (2004) Structural and functional analysis of the costimulatory receptor programmed death-1. Immunity 20:337-347.
13. Youngnak P, et al. (2003) Differential binding properties of B7-H1 and B7-DC to programmed death-1. Biochem Biophys Res Commun 307:672-677.
14. Yamazaki T, et al. (2002) Expression of programmed death 1 ligands by murine T cells and APC. J Immunol 169:5538-5545.
15. Chen L (2004) Co-inhibitory molecules of the B7-CD28 family in the control of T-cell immunity. Nat Rev Immunol 4:336-347.
16. Butte MJ, Keir ME, Phamduy TB, Sharpe AH, Freeman GJ (2007) Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses. Immunity 27:111-122.
17. Schwartz JC, Zhang X, Nathenson SG, Almo SC (2002) Structural mechanisms of costimulation. Nat Immunol 3:427-434.
18. Ikemizu S, et al. (2000) Structure and dimerization of a soluble form of B7-1. Immunity 12:51-60.
19. Stamper CC, et al. (2001) Crystal structure of the B7-1/CTLA-4 complex that inhibits human immune responses. Nature 410:608-611.
20. Wang S, et al. (2003) Molecular modeling and functional mapping of B7-H1 and B7-DC uncouple costimulatory function from PD-1 interaction. J Exp Med 197:1083-1091.
21. Agata Y, et al. (1996) Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes. Int Immunol 8:765-772.
22. Schwartz JC, Zhang X, Fedorov AA, Nathenson SG, Almo SC (2001) Structural basis for co-stimulation by the human CTLA-4/B7-2 complex. Nature 410:604-608.
23. Ostrov DA, Shi W, Schwartz JC, Almo SC, Nathenson SG (2000) Structure of murine CTLA-4 and its role in modulating T cell responsiveness. Science 290:816-819.
24. Evans EJ, et al. (2005) Crystal structure of a soluble CD28-Fab complex. Nat Immunol 6:271-279.
25. Pentcheva-Hoang T, Chen L, Pardoll DM, Allison JP (2007) Programmed death-1 concentration at the immunological synapse is determined by ligand affinity and availability. Proc Natl Acad Sci USA 104:17765-17770.
26. Larsen CP, et al. (2005) Rational development of LEA29Y (belatacept), a high-affinity variant of CTLA4-Ig with potent immunosuppressive properties. Am J Transplant 5:443-453.
27. Vincenti F, et al. (2005) Costimulation blockade with belatacept in renal transplantation. N Engl J Med 353:770-781.
28. Lin DY, et al. (2008) The PD-1/PD-L1 complex resembles the antigen-binding Fv domains of antibodies and T cell receptors. Proc Natl Acad Sci USA 105:3011-3016.